HepCInfo.ca | PositiveSide.ca | LivePositive.ca | TreatHIVGlobally.ca | Resources for Nurses

Living with HIV

For service providers

For health care providers

Access our services

Find organizations

News and events

CATIE Ordering Centre

FRAN�AIS PREVIOUS PAGE NEXT PAGE SUBSCRIBE

TreatmentUpdate

TreatmentUpdate is CATIE's flagship treatment digest on cutting-edge developments in HIV/AIDS research and treatment. ( 8 issues per year.)

Expand list of issues | Collapse list of issues

TU 179 2010 May/June PDF

     I ANTI-HIV AGENTS: A. Raltegravir vs. efavirenz – four years later

     I ANTI-HIV AGENTS: B. Raltegravir vs. efavirenz – focus on lipodystrophy, lipids and other changes

     I ANTI-HIV AGENTS: C. Raltegravir in hepatitis co-infection

     II COMPLICATIONS AND SIDE EFFECTS: A. EuroSIDA study finds a signal of kidney toxicity with tenofovir or atazanavir

TU 178 2010 March/April PDF

     I ANTI-HIV AGENTS - A. The debut of the quad pill

     I ANTI-HIV AGENTS - B. ACTG 5202 — effectiveness of different treatments

     I ANTI-HIV AGENTS - C. ACTG 5224 — changes in bones and fat

     I ANTI-HIV AGENTS - D. Odin — darunavir-ritonavir once or twice daily

     I ANTI-HIV AGENTS - E. Monotherapy with darunavir-ritonavir—the Monet study

     I ANTI-HIV AGENTS - F. Surprising changes in body fat with darunavir monotherapy

TU 177 2010 February PDF

     I. SIDE EFFECTS AND COMPLICATIONS - A. Study finds heart disease in young HIV-positive men

     I. SIDE EFFECTS AND COMPLICATIONS - B. DAD: an updated analysis of heart attack risk

     I. SIDE EFFECTS AND COMPLICATIONS - C. High risk of heart problems in people with kidney dysfunction

     I. SIDE EFFECTS AND COMPLICATIONS - D. Hepatitis C, HIV and the kidneys

     I. SIDE EFFECTS AND COMPLICATIONS - E. Tenofovir and the kidneys

TU 176 2010 January PDF

     I ANTI-HIV AGENTS - A. Massive change in U.S. treatment guidelines

     I ANTI-HIV AGENTS - B. Earlier initiation of therapy recommended

     I ANTI-HIV AGENTS - C. Considering delaying the start of therapy

     I ANTI-HIV AGENTS - D. What to use for initial therapy

     I ANTI-HIV AGENTS - E. Simplifying therapy

     I ANTI-HIV AGENTS - F. What not to use

     I ANTI-HIV AGENTS - G. Acute HIV infection—should it be treated?

     I ANTI-HIV AGENTS - H. Reducing the risk of HIV transmission

     I ANTI-HIV AGENTS - I.�Hepatitis C virus co-infection

     I ANTI-HIV AGENTS - J. Treatment-experienced patients

TU 175 2009 November PDF

     I COMPLICATIONS AND SIDE EFFECTS: A. Inflammation and HIV

     I COMPLICATIONS AND SIDE EFFECTS: B. French study unexpectedly uncovers role of substance use in heart attacks

     I COMPLICATIONS AND SIDE EFFECTS: C. VA study fingers kidney disease as a major predisposing factor for heart attacks

     I COMPLICATIONS AND SIDE EFFECTS: D. BICOMBO study looks at the safety of abacavir

     I COMPLICATIONS AND SIDE EFFECTS: E. Cardiovascular risk and HIV treatment

TU 174 2009 July/August PDF

     I SIDE EFFECTS AND COMPLICATIONS: A. The kidneys

     I SIDE EFFECTS AND COMPLICATIONS: B. Drugs and the kidneys

     I SIDE EFFECTS AND COMPLICATIONS: C. HIV and the kidneys – a look over time

     I SIDE EFFECTS AND COMPLICATIONS: D. Cystatin C for monitoring kidney health

     I SIDE EFFECTS AND COMPLICATIONS: E.�Comparing viruses – HIV and hepatitis C in mostly men

     I SIDE EFFECTS AND COMPLICATIONS: F.�The kidneys and hep C in women

     I SIDE EFFECTS AND COMPLICATIONS: G. Age, tenofovir and the kidneys

     I SIDE EFFECTS AND COMPLICATIONS: H. A large study looks at tenofovir and kidney health

TU 173 2009 May/June PDF

     I ANTI-HIV AGENTS: A. Maturation inhibitor reappears

     I ANTI-HIV AGENTS: B. Raltegravir (Isentress)

     I ANTI-HIV AGENTS: C. Raltegravir—results after two years

     I ANTI-HIV AGENTS: D. Raltegravir as initial therapy

     I ANTI-HIV AGENTS: E. Darunavir—favourable results after two years

     II CANCER: A. Concern about cancer risk with raltegravir

     II CANCER: B. Predicting who is at high risk for lymphoma

TU 172 2009 March/April PDF

     I ANTI-HIV AGENTS - A. The 16th CROI

     I ANTI-HIV AGENTS - B. When is it best to start HAART?

     I ANTI-HIV AGENTS - C. Should HAART begin right after an HIV diagnosis?

     I ANTI-HIV AGENTS - D. Atazanavir and raltegravir—an interesting combination

     I ANTI-HIV AGENTS - E. Are new drug boosters coming?

     I ANTI-HIV AGENTS - F. Gene therapy

     I ANTI-HIV AGENTS - G. A clinical trial of gene therapy for HIV

     II COMPLICATIONS AND SIDE EFFECTS - A. Falling rates of heart attacks

     II COMPLICATIONS AND SIDE EFFECTS - B. France: a large hospital database looks at heart attacks

     II COMPLICATIONS AND SIDE EFFECTS - C. The DAD study: a large European database looks at heart attacks

     II COMPLICATIONS AND SIDE EFFECTS - D. Putting heart attack risk into perspective

TU 171 2009 February PDF

     I ANTI-HIV AGENTS: A. The changing picture of HIV

     I ANTI-HIV AGENTS: B. HAART reduces inflammation in the blood but...

     I ANTI-HIV AGENTS: C. Treatment interruption uncovers HIV’s attack on the kidneys

     II SIDE EFFECTS AND COMPLICATIONS: A. HAART and the safety of the fetus

     II SIDE EFFECTS AND COMPLICATIONS: B. French study clears HAART of cancer link in kids

     II SIDE EFFECTS AND COMPLICATIONS: C. Risk of deformities very low in infants exposed to HAART

TU 170 2009 January PDF

     I. ANTI-HIV AGENTS: A. Starting therapy—looking back

     I. ANTI-HIV AGENTS: B. New evidence changes guidelines about when to start treatment

     I. ANTI-HIV AGENTS: C. A few reasons for starting therapy at CD4+ counts above 350 cells

     I. ANTI-HIV AGENTS: D. Unexpected dangers of drug holidays—the SMART study

     I. ANTI-HIV AGENTS: E. Why are drug holidays dangerous?

     I. ANTI-HIV AGENTS: F. Treatment interruption surprisingly does not reduce heart disease risk

     I. ANTI-HIV AGENTS: G. Reduced inflammation linked to survival

TU 169 2008 August/September PDF

     I ANTI-HIV AGENTS: A. Good news for HAART users

     II ANTI-CANCER AGENTS: A. Kaposi’s sarcoma—past and future

     II ANTI-CANCER AGENTS: B. More about KS

     II ANTI-CANCER AGENTS: C. KS in HIV negative men

     II ANTI-CANCER AGENTS: D. Liposomal chemo for KS

TU 168 2008 June/July PDF

     I CO-INFECTIONS: A. Coming up: updates on hepatitis C

     I CO-INFECTIONS: B. The growing problem of insulin resistance

     I CO-INFECTIONS: C. Risk factors for insulin resistance in hep C

     I CO-INFECTIONS: D. French study finds recovery from hep c blocked by insulin resistance

     I CO-INFECTIONS: E. Dangerous liaisons: risky sex, drugs and hep C

     I CO-INFECTIONS: F. Rapid liver damage after recent HCV co-infection

     I CO-INFECTIONS: G. Some good news about HAART and liver health

     I CO-INFECTIONS: H. Unexpected liver damage—is ddI to blame?

     I CO-INFECTIONS: I. The disturbing issue of HCV re-infection

     I CO-INFECTIONS: J. Predicting recovery from hep C

TU 167 2008 April/May PDF

     I NUTRITION: A. Chromium deficiency in HIV

     I NUTRITION: B. Can chromium supplements help body shape?

     II HORMONES: A. Ovaries—hormone troubles in some HIV positive women

Previous Next


	See also

	CATIE-News What's New? CATIE Publications

Decisions about particular medical treatments should always be made in consultation with a qualified medical practitioner who is knowledgeable about HIV-related illness and the treatments in question. MORE

Privacy | Permission to reproduce | Funders

Production of this Web site has been made possible through a financial contribution from the Public Health Agency of Canada.

We comply with the HONcode standard for trustworthy health information: verify here.